Amount of maximum aggregate milestone commitment fund for first product development.

No definition available.

Name:	limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of maximum milestone commitment fund for each additional product development.

+ References

No definition available.

+ Details

Name:	limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of license milestone commitment fund obligated to pay for each phase.

+ References

No definition available.

+ Details

Name:	limn_LicenseMilestoneCommitmentFundPayableForEachPhase
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of milestone developmental and regulatory milestone payments for each additional product development.

+ References

No definition available.

+ Details

Name:	limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of milestone developmental and regulatory milestone payments for first product development.

+ References

No definition available.

+ Details

Name:	limn_NumberOfMilestonePaymentsForFirstProductDevelopment
Namespace Prefix:	limn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.

+ References

No definition available.

+ Details

Name:	limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts
Namespace Prefix:	limn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty fees

+ References

No definition available.

+ Details

Name:	limn_RoyaltyFeesPercentage
Namespace Prefix:	limn_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.

+ References

No definition available.

+ Details

Name:	limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate
Namespace Prefix:	limn_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront payment of license agreement fee.

+ References

No definition available.

+ Details

Name:	limn_UpfrontPaymentOfLicenseAgreementFees
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of maintenance incurred and directly related to good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostMaintenance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=limn_LiminatusPharmaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - CAR-T Products License (Details) - License And Development Agreement With TDT	1 Months Ended	12 Months Ended
	Jun. 30, 2018 USD ($) Milestone	Dec. 31, 2024 USD ($) item	Dec. 31, 2018 USD ($)
CAR-T products and CAR-T Diagnostics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment of license agreement fees			$ 5,000,000
Annual maintenance fees	$ 500,000
Unpaid annual maintenance fees, short term debt interest rate (%)	1.50%
Number of developmental and regulatory milestone payments for first product development \| Milestone	4
Maximum aggregate milestone commitment fund for first product development	$ 15,000,000
Number of developmental and regulatory milestone payments for each additional product development \| Milestone	4
Maximum milestone commitment fund for each additional product development	$ 7,500,000
CAR-T products and CAR-T Diagnostics \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment of license agreement fees			$ 5,000,000
Annual maintenance fees		$ 500,000
Unpaid annual maintenance fees, short term debt interest rate (%)		1.50%
Number of developmental and regulatory milestone payments for first product development \| item		4
Maximum aggregate milestone commitment fund for first product development		$ 15,000,000
Number of developmental and regulatory milestone payments for each additional product development \| item		4
Maximum milestone commitment fund for each additional product development		$ 7,500,000
CAR-T products and CAR-T Diagnostics \| Net sales of period from first commercial sale until patent expires \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	10.00%
CAR-T products and CAR-T Diagnostics \| Net sales of period from first commercial sale until patent expires \| Minimum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)		10.00%
CAR-T products and CAR-T Diagnostics \| Net sales of period from first commercial sale until patent expires \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	15.00%
CAR-T products and CAR-T Diagnostics \| Net sales of period from first commercial sale until patent expires \| Maximum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)		15.00%
CAR-T products and CAR-T Diagnostics \| 10 years from first commercial sale of products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of years from first commercial sale of products (in years)	10 years
CAR-T products and CAR-T Diagnostics \| 10 years from first commercial sale of products \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of years from first commercial sale of products (in years)		10 years
CAR-T products and CAR-T Diagnostics \| 10 years from first commercial sale of products \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	5.00%
CAR-T products and CAR-T Diagnostics \| 10 years from first commercial sale of products \| Minimum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)		5.00%
CAR-T products and CAR-T Diagnostics \| 10 years from first commercial sale of products \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)	9.00%
CAR-T products and CAR-T Diagnostics \| 10 years from first commercial sale of products \| Maximum \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty fees (%)		9.00%
Phase II and Phase III clinical trials of CAR-T Product \| Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of fund obligated to advance for each phase	$ 20,000,000
Phase II and Phase III clinical trials of CAR-T Product \| Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product \| Liminatus Pharma, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of fund obligated to advance for each phase		$ 20,000,000